microRNA-based silencing of an ALS gene safely delivered to patients

UMass Medical School and Massachusetts General Hospital are the first to safely treat two research participants with a synthetic microRNA, delivered into the spinal fluid, designed to silence a human disease-causing gene. Details of the treatment, which targeted the mutant SOD1 gene that causes ALS, appears in the New England Journal of Medicine.